Int J Gen Med. 2021 Jun 30;14:3069-3077. doi: 10.2147/IJGM.S318087. eCollection 2021.
Hepatitis B Virus-Related Glomerulonephritis with Positive and Negative Serum HBsAg: Different Clinicopathologic Characteristics of Two Clinical Subtypes.
International journal of general medicine
Feng Yu, Guanglan Li, Wenke Hao, Wenxue Hu
Affiliations
Affiliations
- Department of Nephrology, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangdong Provincial Geriatrics Institute, Guangzhou, 510080, People's Republic of China.
- Shantou University Medical College, Shantou, 515041, People's Republic of China.
PMID: 34234535
PMCID: PMC8256109 DOI: 10.2147/IJGM.S318087
Abstract
INTRODUCTION: The clinicopathologic characteristics of Hepatitis B virus-associated glomerulonephritis (HBV-GN) patients with different serum HBsAg are not well known. This study aims to investigate the characteristics and treatments between HBV-GN patients with positive and negative serum HBsAg.
METHODS: A retrospective review of patients with renal biopsies in Guangdong Provincial People's Hospital from 2005 to 2018 was performed. Clinicopathological data, treatments and remission of proteinuria were collected and compared between HBsAg+ and HBsAg- group.
RESULTS: A total of 101 HBV-GN were recruited. Serum HBsAg+ and HBsAg- patients accounted for 62.4% and 37.6%, respectively. HBsAg+ group had poor kidney and liver functions. Pathological data showed the percentage of membranous nephropathy in HBsAg- group is significantly higher than that of HBsAg+ group (60.3% HBsAg+ vs 89.5% HBsAg-,
CONCLUSION: The clinicopathological characteristics and treatments of HBV-GN with serum HBsAg+ and HBsAg- were distinct, which indicated that the pathogenesis might be different and specific treatments were needed for HBV-GN patients with different serum HBsAg.
© 2021 Yu et al.
Keywords: hepatitis B; hepatitis B virus related glomerulonephritis; serum HBsAg
Conflict of interest statement
The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
References
- Expert Rev Gastroenterol Hepatol. 2020 Feb;14(2):113-125 - PubMed
- Sci Rep. 2020 Jul 3;10(1):10994 - PubMed
- Immunogenetics. 2006 Sep;58(9):701-13 - PubMed
- Biomed Res Int. 2019 Mar 26;2019:6869179 - PubMed
- Ann Intern Med. 2009 May 5;150(9):604-12 - PubMed
- Immunol Cell Biol. 2016 Mar;94(3):266-73 - PubMed
- J Gastroenterol Hepatol. 2013 Aug;28 Suppl 1:7-10 - PubMed
- Virol J. 2013 Oct 04;10:300 - PubMed
- Int J Biochem Cell Biol. 2018 Apr;97:62-72 - PubMed
- Liver Int. 2015 Sep;35(9):2082-9 - PubMed
- Kidney Int. 2019 Feb;95(2):281-295 - PubMed
- World J Gastroenterol. 2015 Nov 14;21(42):11941-53 - PubMed
- Lancet. 2018 Nov 24;392(10161):2313-2324 - PubMed
- Adv Chronic Kidney Dis. 2015 Sep;22(5):343-51 - PubMed
- Eur J Gastroenterol Hepatol. 2015 Jan;27(1):65-9 - PubMed
- Kidney Int. 1996 Dec;50(6):1965-77 - PubMed
- Chin Med J (Engl). 2014;127(9):1715-20 - PubMed
- Clin J Am Soc Nephrol. 2017 Sep 7;12(9):1529-1533 - PubMed
- Lancet. 2014 Dec 6;384(9959):2053-63 - PubMed
- Kidney Int. 2017 May;91(5):1014-1021 - PubMed
- Clin Exp Nephrol. 2018 Feb;22(1):3-14 - PubMed
- World J Gastroenterol. 2019 Aug 28;25(32):4764-4778 - PubMed
- Liver Int. 2018 Jan;38(1):23-32 - PubMed
- J Hepatol. 2019 Aug;71(2):397-408 - PubMed
- Chin Med J (Engl). 2018 Mar 20;131(6):731-735 - PubMed
- Int J Infect Dis. 2018 Jun;71:25-29 - PubMed
Publication Types